{"protocolSection": {"identificationModule": {"nctId": "NCT00527514", "orgStudyIdInfo": {"id": "8663-402"}, "organization": {"fullName": "Daiichi Sankyo", "class": "INDUSTRY"}, "briefTitle": "Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension", "officialTitle": "A Prospective, Open-label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects With Stage 1 and Stage 2 Hypertension"}, "statusModule": {"statusVerifiedDate": "2009-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-09"}, "primaryCompletionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-09-10", "studyFirstSubmitQcDate": "2007-09-10", "studyFirstPostDateStruct": {"date": "2007-09-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-05-05", "resultsFirstSubmitQcDate": "2009-08-14", "resultsFirstPostDateStruct": {"date": "2009-09-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2009-11-04", "lastUpdatePostDateStruct": {"date": "2009-11-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "William Waverczak", "oldOrganization": "Daiichi Sankyo"}, "leadSponsor": {"name": "Daiichi Sankyo", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will be conducted to assess the efficacy and safety of an amlodipine/olmesartan treatment regimen in stage 1 and stage 2 hypertensive subjects."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "Angiotensin Receptor Blocker", "Calcium Channel Blocker", "Stage I and II Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 185, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Amlodipine", "Drug: Olmesartan medoxomil plus amlodipine"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine", "description": "Tablets", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Olmesartan medoxomil plus amlodipine", "description": "Tablets", "armGroupLabels": ["1"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring", "timeFrame": "Baseline to 12 Weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg Group.", "description": "Change from study baseline in cuff systolic pressure (as measured by an Omron device) to the end of the treatment period. The Last Observation Carried Forwarded (LOCF) approach was used for the analysis.", "timeFrame": "Baseline to end of week 3"}, {"measure": "Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 20 mg Group.", "description": "Change from study baseline in cuff systolic pressure (as measured by an Omron device) to the end of the treatment period. The Last Observation Carried Forwarded (LOCF) approach was used for the analysis.", "timeFrame": "Baseline to end of week 6"}, {"measure": "Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 40 mg Group", "description": "Change from study baseline in cuff systolic pressure (as measured by an Omron device) to the end of the treatment period. The Last Observation Carried Forwarded (LOCF) approach was used for the analysis.", "timeFrame": "Baseline to end of week 9"}, {"measure": "Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 10 mg + Olmesartan 40 mg Group", "description": "Change from study baseline in cuff systolic pressure (as measured by an Omron device) to the end of the treatment period. The Last Observation Carried Forwarded (LOCF) approach was used for the analysis.", "timeFrame": "Baseline to end end of week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Males or females greater than or equal to 18 years of age\n* Patients with a mean seated systolic blood pressure (MSSBP) greater than or equal to 140 mm Hg but less than or equal to 199 mm Hg or a mean seated diastolic blood pressure (MSDBP) greater than or equal to 90 mm Hg and less than or equal to 109 mm Hg, following a period of taking only placebo\n* Patients with a mean daytime (8AM-4PM) systolic blood pressure greater than or equal to 135 mm Hg and less than or equal to 199 mm Hg and a mean daytime diastolic blood pressure less than or equal to 109 mm Hg as measured by an ambulatory blood pressure monitoring device (ABPM), after a period of taking only placebo\n* If female, must have negative serum pregnancy test at screening and be either post-menopausal (greater than or equal to 1 year), had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study\n\nExclusion Criteria:\n\n* History of stroke or transient ischemic attack (TIA) within the last one year\n* History of myocardial infarction, coronary angioplasty, coronary artery bypass graft, or heart failure within the past 6 months\n* Patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or Cushing's syndrome\n* Type I diabetes. Patients with Type II diabetes on stable treatment, with fasting glucose \\<160 mg/dl may enroll\n* Patients with hemodynamically significant cardiac valvular disease\n* Patients with clinically significant cardiac conduction defects, including second or third degree AV block, left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"city": "Buena Park", "state": "California", "country": "United States", "geoPoint": {"lat": 33.86751, "lon": -117.99812}}, {"city": "Long Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"city": "Sacramento", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"city": "Tustin", "state": "California", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"city": "Westlake Village", "state": "California", "country": "United States", "geoPoint": {"lat": 34.14584, "lon": -118.80565}}, {"city": "Castle Rock", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.37221, "lon": -104.85609}}, {"city": "Pembroke Pines", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.00315, "lon": -80.22394}}, {"city": "Orland Park", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.63031, "lon": -87.85394}}, {"city": "Natick", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 42.28343, "lon": -71.3495}}, {"city": "New York", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"city": "Winston-Salem", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"city": "Beaver", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.69534, "lon": -80.30478}}, {"city": "Greer", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.93873, "lon": -82.22706}}, {"city": "Carrolton", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.95373, "lon": -96.89028}}, {"city": "Corpus Christi", "state": "Texas", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"city": "Madison", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "After placebo treatment, participants with a mean systolic blood pressure (SBP)\u2265140 mmHg and \u2264199 mmHg or a mean diastolic BP (DBP)\u226590 and \u2264109 mmHg with a difference between mean SBPs \u226415 mmHg and a mean 8-hr daytime SBP of \u2265135 mmHg and \u2264199 mmHg, and mean 8-hr daytime DBP of \\<110 mmHg by ambulatory BP monitoring were considered eligible.", "recruitmentDetails": "Participants were recruited at 18 US sites over 4 months (September 2007 to December 2007) from each physician's clientele base. Approximately 150 eligible participants, men and women at least 18 years of age with hypertension or uncontrolled hypertension on current medication, were to receive active treatment", "groups": [{"id": "FG000", "title": "Amlodipine and Olmesartan, if Necessary", "description": "All eligible participants began the active treatment period with amlodipine (Aml) 5 mg for Weeks 1-3. If blood pressure was greater than 120/80 at the end of 3 weeks, participants were titrated to the next regimen for weeks 4-6, and so on for weeks 7-9 and 10-12."}], "periods": [{"title": "Weeks 1-3: Amlodipine (Aml) 5mg", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "185"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "1 participant dropped out. 2 participants were subsequently mis-titrated to the third regimen.", "numSubjects": "184"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}, {"title": "Weeks 4-6: Aml 5mg+Olmesartan 20 mg", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "184 -2 who were mis-titrated -2 who met blood pressure goal = 180", "numSubjects": "180"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "178"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}, {"title": "Weeks 7-9: Aml 5 mg + Olmesartan 40 mg", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "178 -19 who met blood pressure goal + 2 who were mis-titrated = 161", "numSubjects": "161"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "158"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}, {"title": "Weeks 10-12:Aml 10 mg +Olmesartan 40 mg", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "158 -24 who met blood pressure goal = 134", "numSubjects": "134"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "132"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Amlodipine and Olmesartan, if Necessary", "description": "Week 1-3 all participants: Amlodipine 5mg; Week 4-6 Amlodipine 5 mg/olmesartan 20 mg if mean SBP \\>= 120/80 mm Hg; Week 7-9 Amlodipine 5 mg/ olmesartan 40 mg if mean SBP \\>= 120/80 mm Hg; Week 10-12 Amlodipine 10 mg/olmesartan 40 mg if mean SBP \\>= 120/80 mm Hg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "185"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.8", "spread": "9.28"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "80"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "105"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "26"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "144"}]}]}, {"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "185"}]}]}]}, {"title": "Stage of Hypertension", "description": "Stage I hypertension is defined as systolic blood pressure (SBP) of 140 - 159 mmHg and diastolic blood pressure (DBP) of 90 - 99 mmHg; Stage II is defined as SBP \u2265 160 mmHg or DBP \u2265 100 mm Hg.", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Stage 1", "categories": [{"measurements": [{"groupId": "BG000", "value": "82"}]}]}, {"title": "Stage 2", "categories": [{"measurements": [{"groupId": "BG000", "value": "103"}]}]}]}, {"title": "24-Hour Ambulatory Diastolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "85.8", "spread": "7.91"}]}]}]}, {"title": "24-hour Ambulatory Systolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "144.6", "spread": "10.88"}]}]}]}, {"title": "Heart Rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "beats/minute", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "75.1", "spread": "10.82"}]}]}]}, {"title": "Systolic Blood Pressure", "description": "Seated cuff measurement as opposed to ambulatory measurement.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "158.2", "spread": "12.63"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring", "populationDescription": "The ambulatory blood pressure monitoring (ABPM) subset were subjects who received at least one dose of active study medication and had a baseline ABPM and end of study ABPM measurement.This = 172 participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to 12 Weeks", "groups": [{"id": "OG000", "title": "Overall Active Treatment Period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "172"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-21.4", "spread": "0.80"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "The sample size of this study was not based on the statistical power consideration and was considered as sufficient for the evaluation of the efficacy and safety of the proposed olmesartan medoxomil-based treatment regimen.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "No multiplicity adjustments", "statisticalMethod": "one-sample t-test", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure", "populationDescription": "The ambulatory blood pressure monitoring (ABPM) subset were subjects who received at least one dose of active study medication and had a baseline ABPM and end of study ABPM measurement.This = 172 participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Overall Active Treatment Period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "172"}]}], "classes": [{"title": "Daytime", "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.1", "spread": "0.92"}]}]}, {"title": "Nighttime", "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.5", "spread": "0.91"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Statistical analysis parameters apply to both the daytime and nighttime rows.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "No multiplicity adjustments", "statisticalMethod": "One-sample t-test", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg Group.", "description": "Change from study baseline in cuff systolic pressure (as measured by an Omron device) to the end of the treatment period. The Last Observation Carried Forwarded (LOCF) approach was used for the analysis.", "populationDescription": "ITT (efficacy cohort)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of week 3", "groups": [{"id": "OG000", "title": "Group 1 Amlodipine 5 mg", "description": "All participants started the Active Treatment period with 5 mg of amlodipine for 3 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "185"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.1", "spread": "0.97"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "No multiplicity adjustments", "statisticalMethod": "One-sample t-test", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 20 mg Group.", "description": "Change from study baseline in cuff systolic pressure (as measured by an Omron device) to the end of the treatment period. The Last Observation Carried Forwarded (LOCF) approach was used for the analysis.", "populationDescription": "ITT (efficacy cohort)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of week 6", "groups": [{"id": "OG000", "title": "Group 2 - Aml 5 mg + Olmesartan 20 mg", "description": "Participants from Group 1 who did not meet the blood pressure goal after 3 weeks were titrated to Aml 5 mg + olmesartan 20 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-18.0", "spread": "0.92"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "No multiplicity adjustments", "statisticalMethod": "one-sample t-test", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 40 mg Group", "description": "Change from study baseline in cuff systolic pressure (as measured by an Omron device) to the end of the treatment period. The Last Observation Carried Forwarded (LOCF) approach was used for the analysis.", "populationDescription": "ITT (efficacy cohort)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of week 9", "groups": [{"id": "OG000", "title": "Group 3 - Aml 5 mg + Olm 40 mg", "description": "Participants from Group 2 who did not meet the blood pressure goal after 3 weeks were titrated to Aml 5 mg + olmesartan 40mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "160"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.5", "spread": "1.01"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "No multiplicity adjustments", "statisticalMethod": "One-sample t-test", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 10 mg + Olmesartan 40 mg Group", "description": "Change from study baseline in cuff systolic pressure (as measured by an Omron device) to the end of the treatment period. The Last Observation Carried Forwarded (LOCF) approach was used for the analysis.", "populationDescription": "ITT (efficacy cohort)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end end of week 12", "groups": [{"id": "OG000", "title": "Group 4 - Aml 10 mg + Olm 40 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "133"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-24.6", "spread": "1.18"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "No multiplicity adjustments", "statisticalMethod": "one-sample t-test", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "12 week treatment period plus 30 days after the last dose.", "description": "Adverse events (AEs)were collected from the time of signing informed consent to the study and followup period (30 days). AEs were observed by the investigator (Inv) or reported by the participant. The nature of the event, time of onset, duration and intensity were documented together with the Inv assessment of the causal relationship to the drug.", "eventGroups": [{"id": "EG000", "title": "Amlodipine 5 mg", "description": "All eligible participants began the active treatment period with amlodipine (Aml) 5 mg for Weeks 1-3. If blood pressure was greater than 120/80 at the end of 3 weeks, participants were titrated to the next regimen for weeks 4-6, and so on for weeks 7-9 and 10-12.", "seriousNumAffected": 0, "seriousNumAtRisk": 185, "otherNumAffected": 8, "otherNumAtRisk": 185}, {"id": "EG001", "title": "Amlodipine 5mg and Olmesartan 20 mg", "description": "All eligible participants began the active treatment period with amlodipine (Aml) 5 mg for Weeks 1-3. If blood pressure was greater than 120/80 at the end of 3 weeks, participants were titrated to the next regimen for weeks 4-6, and so on for weeks 7-9 and 10-12.", "seriousNumAffected": 0, "seriousNumAtRisk": 180, "otherNumAffected": 23, "otherNumAtRisk": 180}, {"id": "EG002", "title": "Amlodipine 5mg and Olmesartan 40 mg", "description": "All eligible participants began the active treatment period with amlodipine (Aml) 5 mg for Weeks 1-3. If blood pressure was greater than 120/80 at the end of 3 weeks, participants were titrated to the next regimen for weeks 4-6, and so on for weeks 7-9 and 10-12.", "seriousNumAffected": 1, "seriousNumAtRisk": 161, "otherNumAffected": 11, "otherNumAtRisk": 161}, {"id": "EG003", "title": "Amlodipine 10 mg and Olmesartan 40 mg", "description": "All eligible participants began the active treatment period with amlodipine (Aml) 5 mg for Weeks 1-3. If blood pressure was greater than 120/80 at the end of 3 weeks, participants were titrated to the next regimen for weeks 4-6, and so on for weeks 7-9 and 10-12.", "seriousNumAffected": 1, "seriousNumAtRisk": 134, "otherNumAffected": 12, "otherNumAtRisk": 134}], "seriousEvents": [{"term": "Limb amputation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 185}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 134}]}, {"term": "Transient ischemic attack", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 185}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 134}]}], "otherEvents": [{"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 185}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 180}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 161}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 134}]}, {"term": "Joint swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 185}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 180}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 161}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 134}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 185}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 180}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 161}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 134}]}, {"term": "Oedema Peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 185}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 180}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 161}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 134}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 185}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 180}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 161}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 134}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "\"If identified by Daiichi Sankyo, Inc. (DSI), any of DSI's confidential information as defined herein shall be deleted...Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by Study Site.\""}, "pointOfContact": {"title": "John Raia", "organization": "Daiichi Sankyo", "email": "jraia@dsus.com", "phone": "(973) 630-2683"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000437965", "term": "Olmesartan"}, {"id": "D000068557", "term": "Olmesartan Medoxomil"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M91890", "name": "Olmesartan", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M273", "name": "Olmesartan Medoxomil", "asFound": "Sleep hygiene", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}